The American Diabetes 79th Annual Scientific Sessions concluded this week, but the meeting is still making headlines.
It was packed with lectures and presentations of groundbreaking research that got practitioners, patients and even pharmaceutical professionals excited. Below are some of the most talked-about findings on Twitter from the conference.
Vitamin D does not prevent type 2 diabetes.
Following up on observational studies that have indicated an association between low levels of vitamin D and increased risk for type 2 diabetes, this study, called D2d, is the largest study to examine this connection. It found that taking a daily vitamin D supplement does not prevent type 2 diabetes in people who are high risk.
An experimental drug can delay type 1 diabetes.
For the first time, scientists have discovered that it’s possible to delay type 1 diabetes onset in high-risk people by a year or more. The study included 14 days of therapy with the experimental drug teplizumab. At its conclusion, 57 percent of participants in the group that had taken teplizumab were diabetes-free compared to 28 percent of those who’d taken the placebo.
Oral Semaglutide is more effective than Empagliflozin and Liraglutide respectively at reducing blood sugar and boosting weight loss.
Phase 3 trial data for the type 2 diabetes (T2D) drug oral semaglutide, a glucagon-like peptide, shows that it lowers blood sugar better than empagliflozin, a leading sodium glucose co-transporter 2. Additional data indicate that oral semaglutide would produce more weight loss than liraglutide, the daily injectable GLP-1 receptor agonist.
NIH-funded trial finds vitamin D does not prevent type 2 diabetes in people at high risk, National Institutes Health.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes, The New England Journal of Medicine.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial, The Lancet.
Last updated on 10/8/19.